pubmed:abstractText |
A phase II study of a non-steroidal selective aromatase inhibitor, YM511, 4-[N-bromobenzyl]-N-(4H-1,2,4-triazol-4-yl)amino) benzonitrile, was conducted to evaluate the anti-tumor response, dose-dependence of response rate and tolerability in postmenopausal patients with advanced breast cancer.
|
pubmed:affiliation |
Breast Cancer Center, Toyosu Hospital, Showa University School of Medicine, 1-18, Toyosu 4-chome, Koutou-ku, Tokyo 135-8577, Japan. watana_y@yamanouchi.co.jp
|